Three different doses of Niktimvo all had high rates of response among patients with recurrent or refractory ...

World Marrow Donor Day is significant as it highlights the crucial role that bone marrow and stem cell donors play in saving ...

A potentially life-saving cancer treatment is often referred to as the original immunotherapy and it helped pave the way for ...

Chronic graft-versus-host disease (GVHD) remains a rare and unacceptably debilitating autoimmune-like syndrome that afflicts patients in whom a blood disorder or cancer is otherwise cured by means ...

The retrospective analysis found Black patients were more likely to develop severe graft versus host disease (GVHD) and have a higher risk of nonrelapse mortality than White patients after ...

Is Syndax Pharmaceuticals, Inc. a buy after the recent stock decline? Analysts support, upcoming approvals, but expect a ...

Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of ...

Panelists discuss how nurse practitioners educate patients about chronic graft-versus-host disease (cGVHD) and its long-term effects, exploring various educational resources and materials such as ...

GVHD is a common and often fatal complication that can follow a bone marrow transplant, which occurs when the donated cells mount an immune response against the transplant recipient’s tissues ...

The conditioning regimen was designed to be reduced-toxicity myeloablative and did not include serotherapy. Graft-versus-host disease (GVHD) prophylaxis initially comprised a calcineurin inhibitor ...

The digital twin trial arm demonstrated a 52.7% overall response rate at 6 months for prednisone in chronic GVHD, aligning with real-world data.

Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.